Home Cart Sign in  
Chemical Structure| 443913-73-3 Chemical Structure| 443913-73-3

Structure of Vandetanib
CAS No.: 443913-73-3

Chemical Structure| 443913-73-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity with an IC50 of 40 nM. Vandetanib also inhibits the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM).

Synonyms: ZD6474; CH 331; Zactima

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vandetanib

CAS No. :443913-73-3
Formula : C22H24BrFN4O2
M.W : 475.35
SMILES Code : CN1CCC(COC2=CC3=NC=NC(NC4=CC=C(Br)C=C4F)=C3C=C2OC)CC1
Synonyms :
ZD6474; CH 331; Zactima
MDL No. :MFCD07772346
InChI Key :UHTHHESEBZOYNR-UHFFFAOYSA-N
Pubchem ID :3081361

Safety of Vandetanib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Vandetanib

RTK

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, IC50:500 nM

  • VEGFR3

    VEGFR3, IC50:110 nM

  • VEGFR2

    VEGFR2, IC50:40 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A2780 cells 500, 750, 1000, 2000, 5000 nM 72 h To test the inhibitory effect of Vandetanib on A2780 cells expressing RET mutants, the results showed that Vandetanib significantly reduced cell viability in a dose-dependent manner. PMC7092606
CALU-3 cells 1 μM 12 months To study the acquired resistance mechanisms of CALU-3 cells to Vandetanib, results showed that CALU-3 cells developed acquired resistance after long-term exposure to Vandetanib, accompanied by epithelial-mesenchymal transition (EMT) features. PMC3172903
HEK293T cells 10 μM 44 h Vandetanib remarkably reduced SARS-CoV-2 propagation and restored SARS-CoV-2-induced aberrant OXPHOS process and ATP generation. PMC11088672
8505C 0.59-150 μM 72 h Vandetanib significantly inhibited the proliferation of 8505C cells, with a GI50 value of 7.56 μM. PMC3079006
Hth83 0.59-150 μM 72 h Vandetanib significantly inhibited the proliferation of Hth83 cells, with a GI50 value of 3.30 μM. PMC3079006
K562 cells 0.78, 1.56, 3.12 μM 48 h Vandetanib downregulated EPHB4 protein via the ubiquitin-proteasome pathway and inhibited PI3K/AKT and MAPK/ERK signaling pathways in K562 cells. PMC9297786
H9 cells 0.78, 1.56, 3.12 μM 48 h Vandetanib significantly inhibited the growth of H9 cells, and its effect was correlated with the expression level of EPHB4. PMC9297786
MEG-01 cells 0.30, 0.60, 1.20 μM 48 h Vandetanib significantly inhibited the growth of MEG-01 cells and induced apoptosis. PMC9297786
MCF-7 10 μM 48 h To evaluate the effect of Vandetanib on RET signaling pathway in hormone-sensitive MCF-7 cells and its impact on cell viability. Results showed that Vandetanib significantly reduced phosphorylated RET levels and cell viability without altering total RET expression. Additionally, Vandetanib enhanced the inhibitory effect of Tamoxifen. PMC3989441
BT-474 10 μM 48 h To evaluate the effect of Vandetanib on RET signaling pathway in hormone-resistant BT-474 cells and its impact on cell viability. Results showed that Vandetanib significantly reduced phosphorylated RET levels and cell viability without altering total RET expression. Additionally, Vandetanib enhanced the inhibitory effect of Tamoxifen. PMC3989441
HCC827 cells 1 μM Vandetanib almost completely diminished EGFR phosphorylation in HCC827 cells. PMC2893040
A549 cells 1 μM Vandetanib caused only a partial reduction in EGFR activation in A549 cells. PMC2893040
H1975 cells 1 μM Neither erlotinib nor vandetanib treatment resulted in significant decreases in EGFR phosphorylation in H1975 cells. PMC2893040

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice CALU-3 cell xenograft model Oral 15 mg/kg Twice daily, 5 days per week, for 5 weeks To evaluate the antitumour efficacy of the MEK inhibitor MSC19363669B in the CALU-3 cell xenograft model, results showed that MSC19363669B significantly inhibited tumour growth. PMC3172903
hACE2 transgenic mice SARS-CoV-2 infection model Oral 25 mg/kg Once daily for 6 days Vandetanib significantly reduced SARS-CoV-2 propagation in lung tissue and mitigated SARS-CoV-2-induced lung inflammation. PMC11088672
Nude mice ATC xenograft model Oral gavage 50 mg/kg, 25 mg/kg Daily for 3-4 weeks Vandetanib significantly inhibited the growth of ATC xenograft tumors, with tumor volume reductions of 69.32% and 66.56% for Hth83 and 8505C, respectively. PMC3079006
BALB/c-nu mice K562 xenograft model Oral 40 mg/kg Once daily for 14 days Vandetanib significantly inhibited tumor growth in the K562 xenograft model and induced tumor cell apoptosis. PMC9297786
Mice MCF-7 xenograft model Oral 25 mg/kg Daily for 3 weeks To evaluate the effect of Vandetanib on tumor growth and metastasis in the MCF-7 xenograft model. Results showed that Vandetanib significantly inhibited tumor growth and reduced tumor cells in the lung. Additionally, Vandetanib reduced activation of ERK1/2 and AKT and increased tumor cell apoptosis. PMC3989441
Nude mice NSCLC xenograft models Oral 50 mg/kg Daily Vandetanib significantly inhibited tumor growth in the HCC827 xenograft model, even showing complete tumor regression in larger tumors. In the HCC827-T790M model, vandetanib delayed the emergence of resistance. In the A549 model, vandetanib and bevacizumab/erlotinib combination therapy were more effective than erlotinib or bevacizumab alone. In the H1975 model, both vandetanib and bevacizumab significantly inhibited tumor growth. PMC2893040
mice MYCN/AlkF1178L neuroblastoma model oral 30 mg/kg daily treatment To evaluate the inhibitory effect of the combination of crizotinib and vandetanib on MYCN/AlkF1178L neuroblastoma, the results showed that the combination therapy was more effective than crizotinib alone, significantly inhibiting tumor growth and prolonging the survival of mice. PMC6168456

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02142036 Metastatic Cancer Phase 2 Active, not recruiting January 2022 Norway ... More >> Akershus University Hospital Lillestrøm, Norway, 1478 The Norwegian Radium Hospital Oslo, Norway, 0379 Less <<
NCT03413176 - Completed - France ... More >> AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM. Paris, France, 75013 Less <<
NCT02788201 Urothelial Carcinoma ... More >> Bladder Cancer Urinary Bladder Neoplasms Less << Phase 2 Recruiting July 1, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT00499850 Advanced Colorectal Carcinoma Phase 1 Completed - Australia ... More >> Research Site East Melbourne, Australia Research Site Footscray, Australia Research Site Heidelberg, Australia Research Site Parkville, Australia Less <<
NCT02117167 Non-small Cell Lung Cancer Met... More >>astatic Less << Phase 2 Recruiting February 2022 France ... More >> Centre Hospitalier Henri Duffau Recruiting Avignon, France Contact: Nicolas CLOAREC, MD       nicolas.cloarec@ch-avignon.fr    Principal Investigator: Nicolas CLOAREC, MD          Centre Hospitalier Universitaire de Besancon - Hopital Jean Minjoz Recruiting Besancon, France Contact: Virginie WESTEEL, MD       virginie.westeel@univ.fcomte.fr    Principal Investigator: Virginie WESTEEL, MD          Hôpital Avicenne Recruiting Bobigny, France Contact: Boris DUCHEMANN, MD       boris.duchemann@aphp.fr    Principal Investigator: Boris DUCHEMANN, MD          Institut Bergonié Recruiting Bordeaux, France Contact: François Chomy, MD       f.chomy@bordeaux.unicancer.fr    Principal Investigator: François Chomy, MD          Hôpital Ambroise Paré Recruiting Boulogne Billancourt, France Contact: Etienne GIROUX LEPRIEUR, MD       etienne.giroux-leprieur@aphp.fr    Principal Investigator: Etienne GIROUX LEPRIEUR, MD          Hospices Civils de Lyon- Hôpital Louis Pradel Recruiting Bron, France Contact: Nicolas Girard, MD       nicolas.girard@chu-lyon.fr    Principal Investigator: Nicolas Girard, MD          Centre François Baclesse Recruiting Caen, France Contact: Radj Gervais, MD       r.gervais@baclesse.unicancer.fr    Principal Investigator: Radj Gervais, MD          CHU Caen Recruiting Caen, France Contact: Gérard Zalcman, MD       zalcman-g@chu-caen.fr    Principal Investigator: Gérard Zalcman, MD          Chu de Caen - Hopital Cote de Nacre Recruiting Caen, France Contact: Jeannick MADELAINE, MD       madelaine-j@chu-caen.fr    Principal Investigator: Jeannick MADELAINE, MD          Hôpital Louis Pasteur Recruiting Chartres, France Contact: Claire Lethrosne, MD       clethrosne@ch-chartres.fr    Principal Investigator: Claire Lethrosne, MD          centre Jean Perrin Recruiting Clermont-Ferrand, France Contact: Xavier Durando, MD       xavier.durando@cjp.fr    Principal Investigator: Xavier Durando, MD          CHU Clermont Ferrand - Hôpital Gabriel Montpied Recruiting Clermont-Ferrand, France Contact: Henri Janicot, MD       hjanicot@chu-clermontferrand.fr    Principal Investigator: Henri Janicot, MD          Hopitaux Civils de Colmar Recruiting Colmar, France Contact: Lionel MOREAU, MD       lionel.moreau@ch-colmar.fr    Principal Investigator: Lionel MOREAU, MD          Centre Hopsitalier Intercommunal de Créteil Recruiting Créteil, France Contact: Isabelle Monnet, MD       isabelle.monnet@chicreteil.fr    Principal Investigator: Isabelle Monnet, MD          Centre Georges François Leclerc Recruiting Dijon, France Contact: Bruno Coudert, MD       bcoudert@cgfl.fr    Principal Investigator: Bruno Coudert, MD          CHU Grenoble Recruiting Grenoble, France Contact: Denis Moro-Sibilot, MD       Dmoro-Sibilot@chu-grenoble.fr    Principal Investigator: Denis Moro-Sibilot, MD          Chd Vendee Recruiting La Roche Sur Yon, France Contact: Tifenn L'HARIDON, MD          Principal Investigator: Tifenn L'HARIDON, MD          CH du Mans Recruiting Le Mans, France Contact: Olivier Molinier, MD       omolinier@ch-lemans.fr    Principal Investigator: Olivier Molinier, MD          Centre Oscar Lambret Recruiting Lille, France Contact: Eric Dansin, MD       e-dansin@o-lambret.fr    Principal Investigator: Eric Dansin, MD          CHRU de Lille Recruiting Lille, France Contact: Alexis Cortot, MD       Alexis.CORTOT@CHRU-LILLE.FR    Principal Investigator: Alexis Cortot, MD          Centre Léon Bérard Recruiting Lyon, France Contact: Maurice Pérol, MD       maurice.perol@lyon.unicancer.fr    Principal Investigator: Maurice Pérol, MD          Hôpital Nord Recruiting Marseille, France Contact: Fabrice Barlesi, MD       fabrice.barlesi@ap-hm.fr    Principal Investigator: Fabrice Barlési, MD          Institut Paoli Calmettes Recruiting Marseille, France Contact: Anne MADROSZYK, MD       madroszyka@ipc.unicancer.fr    Principal Investigator: Anne MADROSZYK, MD          Institut de cancérologie de l'Ouest Recruiting Nantes, France Contact: Jaafar Bennouna, MD       jaafar.bennouna@ico.unicancer.fr    Principal Investigator: Jaafar Bennouna, MD          Centre Antoine Lacassagne Recruiting Nice, France Contact: Josiane OTTO, MD       josiane.otto@nice.unicancer.fr    Principal Investigator: Josiane OTTO, MD          Chr Orleans Recruiting Orleans, France Contact: Hugues MOREL, MD       hugues.morel@chr-orleans.fr    Contact: , MD          Principal Investigator: Hugues MOREL          AH-HP Hôpital Saint Louis Recruiting Paris, France Contact: Damien Pouessel, MD       damien.pouessel@sls.aphp.fr    Principal Investigator: Damien Pouessel, MD          AP-HP Hôpital Cochin Recruiting Paris, France Contact: Jeanne Chapron, MD       jeanne.chapron@cch.aphp.fr    Principal Investigator: Jeanne Chapron, MD          AP-HP Hôpital Européen Georges Pompidou Withdrawn Paris, France AP-HP Hôpital Tenon Recruiting Paris, France Contact: Marie Wislez, MD       marie.wislez@tnn.aphp.fr    Principal Investigator: Marie Wislez, MD          Institut Curie Recruiting Paris, France Contact: Catherine Daniel, MD       catherine.daniel@curie.fr    Principal Investigator: Catherine Daniel, MD          Centre Hospitalier de Pau Recruiting PAU, France Contact: Aldo RENAULT, MD       aldo.renault@ch-pau.fr    Principal Investigator: Aldo RENAULT, MD          Centre Hospitalier Lyon Sud Recruiting Pierre Bénite, France Contact: Jean-Pierre Souquet, MD       pierre-jean.souquet@chu-lyon.fr    Principal Investigator: Jean-Pierre Souquet, MD          CHR Pontchailloux Withdrawn Rennes, France Chru Strasbourg - Nouvel Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD          Principal Investigator: Philippe BARTHELEMY, MD          CHI de Toulon - Hôpital Sainte-Musse Recruiting Toulon, France Contact: Xavier TCHIKNAVORIAN, MD          Principal Investigator: Xavier TCHIKNAVORIAN, MD          CHU Toulouse -Hôpital Larrey Recruiting Toulouse, France Contact: Julien Mazières, MD       mazieres.j@chu-toulouse.fr    Principal Investigator: Julien Mazières, MD          Hôpital Bretonneau Recruiting Tours, France Contact: Eric Pichon, MD       e.pichon@chu-tours.fr    Principal Investigator: Eric Pichon, MD          Gustave Roussy Recruiting Villejuif, France Contact: Benjamin Besse, MD       Benjamin.BESSE@gustaveroussy.fr    Principal Investigator: Benjamin Besse, MD          Sub-Investigator: Jean-Charles Soria, MD Less <<
NCT02299999 Metastatic Breast Cancer Phase 2 Recruiting December 2022 France ... More >> Institut de Cancérologie de l'Ouest/Paul Papin Recruiting Angers, France Contact: Mario CAMPONE, MD       mario.campone@ico.unicancer.fr    Principal Investigator: Mario CAMPONE, MD          Institut Sainte-Catherine Recruiting Avignon, France Contact: Alice Mege, MD       a.mege@isc84.org    Principal Investigator: Alice Mege, MD          Polyclinique Bordeaux Nord Aquitaine Recruiting Bordeaux, France, 33077 Contact: Nadine DOHOLLOU, MD       n.dohollou@bordeauxnord.com    Contact: Nadine DOHOLLOU, MD          Institut Bergonié Recruiting Bordeaux, France Contact: Hervé Bonnefoi, MD       h.bonnefoi@bordeaux.unicancer.fr    Principal Investigator: Hervé Bonnefoi, MD          Centre François Baclesse Recruiting Caen, France Contact: Christelle Lévy, MD       c.levy@baclesse.unicancer.fr    Principal Investigator: Christelle Lévy, MD          Centre Jean Perrin Recruiting Clermont-Ferrand, France Contact: Marie-Ange Mouret Reynier, MD       marie-ange.mouret-reynier@cjp.fr    Principal Investigator: Marie-Ange Mouret Reynier, MD          Ch Alpes Leman Not yet recruiting Contamine Sur Arve, France, 74130 Contact: Carol ALLIOT, MD       calliot@ch-alpes-leman.fr    Contact: Carol ALLIOT, MD          Centre Georges François Leclerc Recruiting Dijon, France, 21079 Contact: Nicolas Isambert, MD       nisambert@cgfl.fr    Principal Investigator: Nicolas Isambert, MD          Chd Vendee Recruiting La Roche-sur-Yon, France, 85925 Contact: Tifenn L'Haridon, MD       tifenn.lharidon@chd-vendee.fr    Contact: Tifenn L'Haridon, MD          Centre Oscar Lambret Recruiting Lille, France Contact: Nuria KOTECKI, MD          Principal Investigator: Nuria KOTECKI, MD          Chu Dupuytren Not yet recruiting Limoges, France, 87000 Contact: Laurence VENAT-BOUVET, MD       laurence.venat-bouvet@chu-limoges.fr    Contact: Laurence VENAT-BOUVET, MD          Hopital Privé Jean Mermoz Not yet recruiting Lyon, France, 69008 Contact: Olfa DERBEL, MD       o.derbelmermoz@gmail.com    Contact: Olfa DERBEL, MD          Centre Hospitalier Lyon Sud Recruiting Lyon, France Contact: Benoit You, MD          Principal Investigator: Benoit You, MD          Centre Léon Bérard Recruiting Lyon, France Contact: Thomas Bachelot, MD       thomas.bachelot@lyon.unicancer.fr    Principal Investigator: Thomas Bachelot, MD          Institut Paoli Calmettes Recruiting Marseille, France Contact: Anthony Gonçalves, MD       goncalvesa@ipc.unicancer.fr    Principal Investigator: Anthony Gonçalves, MD          Institut Régional du Cancer Montpellier Val d'Aurelle Recruiting Montpellier, France Contact: William Jacot, MD       william.jacot@icm.unicancer.fr    Principal Investigator: William Jacot, MD          Centre Alexis Vautrin Recruiting Nancy, France Contact: Elisabeth Luporsi, MD       e.luporsi@nancy.unicancer.fr    Principal Investigator: Elisabeth Luporsi, MD          Institut de Cancérologie de l'Ouest/ René Gauducheau Recruiting Nantes, France Contact: Mario Campone, MD       mario.campone@ico.unicancer.fr    Principal Investigator: Mario Campone, MD          Centre Antoine Lacassagne Recruiting Nice, France Contact: Jean-Marc Ferrero, MD       jean-marc.ferrero@nice.unicancer.fr    Principal Investigator: Jean-Marc Ferrero, MD          Institut Curie Recruiting Paris, France Contact: Marie-Paule Sablin, MD       mariepaule.sablin@curie.fr    Principal Investigator: Marie-Paule Sablin, MD          Centre Eugène Marquis Recruiting Rennes, France Contact: Claudia Lefeuvre-Plesse, MD       c.lefeuvre@rennes.unicancer.fr    Principal Investigator: Claudia Lefeuvre-Plesse, MD          Centre Henri Becquerel Recruiting Rouen, France Contact: Jean-Christophe Théry, MD          Principal Investigator: Jean-Christophe Théry, MD          Institut Curie Recruiting Saint-Cloud, France Contact: Florence COUSSY, MD       florence.coussy@curie.fr    Principal Investigator: Florence COUSSY, MD          Hopitaux Universitaire de Strasbourg - Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD       philippe.barthelemy@chru-strasbourg.fr    Principal Investigator: Philippe BARTHELEMY, MD          Hopitaux Du Leman Recruiting Thonon-les-Bains, France, 74200 Contact: Francesco DEL PIANO, MD       f-delpiano@ch-hopitauxduleman.fr    Contact: Francesco DEL PIANO, MD          Institut Claudius Regaud Recruiting Toulouse, France Contact: Florence Dalenc, MD       dalenc.florence@iuct-oncopole.fr    Principal Investigator: Florence Dalenc, MD          Gustave Roussy Recruiting Villejuif, France Contact: Monica Arnedos, MD       Monica.ARNEDOS@gustaveroussy.fr    Principal Investigator: Monica Arnedos, MD          Sub-Investigator: Fabrice André, MD Less <<
NCT00496509 Colorectal Cancer Phase 1 Completed - Germany ... More >> Research Site Freiberg, Germany Less <<
NCT00290537 - Terminated(Accrual was subopti... More >>mal and increasing the number of patients was not feasible.) Less << - -
NCT01838642 Thyroid Neoplasms Phase 2 Terminated(Recruiting halted p... More >>rematurely and will not resume. New study to open soon.) Less << - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01838642 - Terminated(Recruiting halted p... More >>rematurely and will not resume. New study to open soon.) Less << - -
NCT02638428 Relapsed Pediatric Solid Tumor... More >> Refractory Pediatric Solid Tumor Relapsed Pediatric AML Refractory Pediatric AML Less << Phase 2 Recruiting December 2023 Korea, Republic of ... More >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Ki Woong Sung    82-2-3410-3529    kwsped@skku.edu    Principal Investigator: Ki Woong Sung Less <<
NCT00290537 Lung Cancer Phase 2 Terminated(Accrual was subopti... More >>mal and increasing the number of patients was not feasible.) Less << - United States, Texas ... More >> University of Texas M.D.Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00533169 Neuroblastoma Phase 1 Terminated(Lack of enrollment.... More >>) Less << - United States, Texas ... More >> U.T.M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00252746 Non Small Cell Lung Carcinoma Phase 2 Completed - Japan ... More >> Research Site Matsuyama, Ehime, Japan Research Site Isehara, Kanagawa, Japan Research Site Osakasayama, Osaka, Japan Research Site Toyonaka, Osaka, Japan Research Site Sunto-gun, Shizuoka, Japan Research Site Okayama, Japan Research Site Tokyo, Japan Less <<
NCT02013089 Gastrointestinal Cancers Not Applicable Unknown December 2017 China, Guangdong ... More >> Gastrointestinal Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510655 Contact: Yanghong Deng, PhD    008613925106525    13925106525@163.com    Principal Investigator: Yanhong Deng, PhD Less <<
NCT00066313 Lung Cancer Phase 2 Completed - Canada, Alberta ... More >> Tom Baker Cancer Centre - Calgary Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute at University of Alberta Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 Fraser/Valley Cancer Centre at British Columbia Cancer Agency Surrey, British Columbia, Canada, V3V 1Z2 British Columbia Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, New Brunswick Moncton Hospital Moncton, New Brunswick, Canada, E1C 6ZB Saint John Regional Hospital Saint John, New Brunswick, Canada, E2L 4L2 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston General Hospital Kingston, Ontario, Canada, K7L 5P9 Ottawa Hospital Regional Cancer Centre - General Campus Ottawa, Ontario, Canada, K1H 8L6 St. Catharines General Hospital at Niagara Health System St. Catharines, Ontario, Canada, L2R 5K3 Northwestern Ontario Regional Cancer Care at Thunder Bay Regional Health Sciences Centre Thunder Bay, Ontario, Canada, P7B 6V4 Toronto East General Hospital Toronto, Ontario, Canada, M4C 3E7 Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Windsor Regional Cancer Centre at Windsor Regional Hospital Windsor, Ontario, Canada, N8W 2X3 Canada, Quebec Hopital Notre- Dame du CHUM Montreal, Quebec, Canada, H2L 4M1 McGill Cancer Centre at McGill University Montreal, Quebec, Canada, H2W 1S6 L'Hopital Laval Ste-Foy, Quebec, Canada, G1V 4G5 Canada, Saskatchewan Saskatoon Cancer Centre at the University of Saskatchewan Saskatoon, Saskatchewan, Canada, S7N 4H4 Less <<
NCT00410189 Lung Cancer PHASE2 COMPLETED 2025-03-13 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT00745732 Non-Small Cell Lung Cancer Phase 1 Terminated(Sponsor withdrew su... More >>pport.) Less << - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00659438 Prostate Cancer Phase 2 Completed - France ... More >> Research Site Bordeaux Cedex, France Research Site Creteil, France Research Site Paris, France Research Site Reims Cedex, France Research Site Villejuif, France Less <<
NCT02239952 Cancer High-g... More >>rade Glioma Less << Not Applicable Recruiting January 2019 Netherlands ... More >> VU University Medical Center Recruiting Amsterdam, Noord-Holland, Netherlands, 1081 HV Contact: H.M.W Verheul, MD, PhD    +31 (0)20 4444321    h.verheul@vumc.nl Less <<
NCT00613054 Glioblastoma ... More >>Gliosarcoma Less << Phase 1 Completed - United States, North Carolina ... More >> Duke University Health System Durham, North Carolina, United States, 27710 Less <<
NCT00358956 Thyroid Cancer Phase 2 Completed - United States, Arkansas ... More >> Research Site Little Rock, Arkansas, United States United States, Massachusetts Research Site Boston, Massachusetts, United States Australia Research Site St Leonards, Australia Canada, Quebec Research Site Sherbrooke, Quebec, Canada Italy Research Site Pisa, Italy Netherlands Research Site Utrecht, Netherlands Romania Research Site Bucharest, Romania Spain Research Site Madrid, Spain Switzerland Research Site Basel, Switzerland Less <<
NCT00358956 - Completed - -
NCT00496665 Metastatic Breast Cancer Phase 1 Completed - United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Massachusetts General Hospital Boston, Massachusetts, United States, 02215 Less <<
NCT00410189 Lung Cancer PHASE2 COMPLETED 2025-03-13 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT00404924 Non-Small-Cell Lung Carcinoma Phase 3 Completed - -
NCT00659438 - Completed - -
NCT00811369 Metastatic Breast Cancer Phase 2 Completed - Canada, Alberta ... More >> Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia British Columbia Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Nova Scotia QE II Health Sciences Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Grand River Regional Cancer Centre Kitchener, Ontario, Canada, N2G 1G3 RSM Durham Regional Cancer Centre Oshawa, Ontario, Canada, L1G 2B9 Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Regional Cancer Program of the Hôpital régional de Sudbury Regional Hospital Sudbury, Ontario, Canada, P3E 5J1 Odette Cancer Centre - Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 St. Michael's Hospital Toronto, Ontario, Canada, M5B 1W8 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Centre Hospitalier De L'Universite De Montreal - Hotel Dieu Montreal, Quebec, Canada, H2W 1T7 Canada, Saskatchewan Saskatoon Cancer Centre Saskatoon, Saskatchewan, Canada, S7N 4H4 Less <<
NCT00454116 Colorectal Cancer Phase 2 Completed - United States, Michigan ... More >> Research Site Ann Arbor, Michigan, United States United States, New York Research Site New York, New York, United States United States, Tennessee Research Site Nashville, Tennessee, United States United States, Utah Research Site Salt Lake City, Utah, United States Argentina Research Site Buenos Aires, Argentina Research Site Ramos Mejia, Argentina Research Site Rosario, Argentina Research Site Santa Fe, Argentina Research Site Vicente Lopez, Argentina Korea, Republic of Research Site Seoul, Korea, Republic of Norway Research Site Bergen, Norway Research Site Oslo, Norway Research Site Stavanger, Norway Spain Research Site A Coruna, Spain Research Site Barcelona, Spain Research Site Jaen, Spain Research Site Lerida, Spain Research Site Lleida, Spain United Kingdom Research site Belfast, Northern Ireland, United Kingdom Research Site Aberdeen, United Kingdom Research Site Leicester, United Kingdom Research Site Manchester, United Kingdom Less <<
NCT00454116 - Completed - -
NCT00364351 Non Small Cell Lung Cancer Phase 3 Completed - -
NCT00498797 Prostate Cancer ... More >> Metastatic Hormone Refractory Less << Phase 2 Completed - Brazil ... More >> Research site Rio de Janeiro, Brazil Research Site Sao Paulo, Brazil Germany Research Site Hamburg, Germany Research Site Hannover, Germany Research Site Kassel, Germany Research Site Tubingen, Germany Hungary Research Site Budapest, Hungary South Africa Research Site Bloemfontein, South Africa Research Site Cape Town, South Africa Sweden Research Site Umea, Sweden Research Site Uppsala, Sweden Less <<
NCT03630120 Thyroid Cancer ... More >> Thyroid Cancer, Medullary Differentiated Thyroid Cancer Papillary Thyroid Cancer Follicular Thyroid Cancer Poorly Differentiated Thyroid Gland Carcinoma Less << Phase 2 Recruiting December 2023 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Less <<
NCT00364351 - Completed - -
NCT00494481 - Completed - -
NCT00404924 - Completed - -
NCT00494481 Advanced Breast Cancer Phase 2 Completed - Hungary ... More >> Research Site Budapest, Hungary Research Site Pécs, Hungary South Africa Research SIte Bloemfontein, South Africa Research Site Cape Town, South Africa Research Site Observatory, South Africa Spain Research Site Baracaldo, Spain Research SIte Lérida, Spain Research Site Zaragoza, Spain Sweden Research Site Umeå, Sweden Research Site Uppsala, Sweden Research Site Västerås, Sweden Taiwan Research Site Taipei, Taiwan Less <<
NCT00410761 Thyroid Cancer Phase 3 Active, not recruiting December 31, 2019 -
NCT00410761 - Active, not recruiting - -
NCT00450138 Head and Neck Cancer Phase 1 Completed - United States, Colorado ... More >> Research Site Denver, Colorado, United States United States, Illinois Research Site Chicago, Illinois, United States United States, Texas Research Site Dallas, Texas, United States Research Site Houston, Texas, United States Less <<
NCT00681798 Pancreatic Cancer PHASE1 COMPLETED 2025-06-09 Research Site, St Gallen, SG, ... More >>Switzerland|Research Site, Bellinzona, Switzerland Less <<
NCT00507091 Metastatic Co... More >>lorectal Adenocarcinoma Less << Phase 1 Completed - Belgium ... More >> Research Site Gent, Belgium United Kingdom Research Site Belfast, United Kingdom Research Site Manchester, United Kingdom Less <<
NCT00312377 Non-small Cell Lung Cancer ... More >> Lung Cancer Less << Phase 3 Completed - -
NCT00503711 Advanced Solid, Malignant Tumo... More >>rs Less << Phase 1 Completed - China ... More >> Research Site Guangzhou, China Less <<
NCT00459121 Lung Cancer Phase 2 Terminated - United States, Michigan ... More >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 Less <<
NCT00312377 - Completed - -
NCT00418886 Non Small Cell Lung Cancer ... More >> Lung Cancer Less << Phase 3 Active, not recruiting December 2019 -
NCT00601614 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Withdrawn(no enrollment) - -
NCT00418886 - Active, not recruiting - -
NCT00498797 - Completed - -
NCT00686036 Prostate Cancer Phase 2 Terminated(Slow recruitment) - Canada, Alberta ... More >> Research Site Calgary, Alberta, Canada Research Site Edmonton, Alberta, Canada Canada, British Columbia Research Site Victoria, British Columbia, Canada Canada, Ontario Research Site Hamilton, Ontario, Canada Research Site Kingston, Ontario, Canada Research Site London, Ontario, Canada Research Site Toronto, Ontario, Canada Canada, Quebec Research Site Greenfield Park, Quebec, Canada Research Site Montreal, Quebec, Canada Research Site Sherbrooke, Quebec, Canada Canada Research Site Granby, Canada Less <<
NCT00459121 - Terminated - -
NCT00686036 - Terminated(Slow recruitment) - -
NCT00752986 Breast Cancer Phase 2 Terminated - Italy ... More >> Research Site Avellino, Italy Research Site Benevento, Italy Research Site Genova, Italy Research Site Milano, Italy Research Site Monserrato, Italy Research Site Napoli, Italy Research Site Palermo, Italy Research Site Prato, Italy Research Site Roma, Italy Research Site Trento, Italy Research Site Varese, Italy Less <<
NCT00506051 Carcinoma Non... More >>-Small Cell Lung Lung Cancer Less << Phase 1 Completed - -
NCT00752986 - Terminated - -
NCT00481845 Breast Cancer Phase 2 Terminated(Low accrual) - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT00937417 Breast Cancer ... More >> Head and Neck Cancer Lung Cancer Prostate Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Withdrawn(Withdrawn because SW... More >>OG no longer pursuing this study at this time) Less << September 2009 -
NCT00481845 - Terminated(Low accrual) - -
NCT00734890 Lung Cancer L... More >>ymphoma Lymphoproliferative Disorder Small Intestine Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 Less <<
NCT00098345 Thyroid Cancer Phase 2 Completed - United States, California ... More >> Research Site San Francisco, California, United States United States, Connecticut Research Site New Haven, Connecticut, United States United States, New York Research Site New York, New York, United States United States, North Carolina Research Site Durham, North Carolina, United States United States, Texas Research Site Houston, Texas, United States France Research Site Villejuif Cedex, France Less <<
NCT01414426 Lip and Oral Cavity Squamous C... More >>ell Carcinoma Oral Cavity Verrucous Carcinoma Precancerous Condition Less << Phase 2 Active, not recruiting March 2018 United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT00508001 - Completed - -
NCT00597116 Mesothelioma Phase 2 Terminated(Recruitment stopped... More >> according to early stopping rule (by protocol)) Less << - Germany ... More >> Research Site Essen, Germany Research Site Halle-Dolau, Germany Research Site Hamburg, Germany Research Site Heidelberg, Germany Switzerland Research Site Chur, Switzerland Research Site Zurich, Switzerland Less <<
NCT00732745 Adenocarcinoma of the Gastroes... More >>ophageal Junction Esophageal Cancer Less << Phase 1 Terminated(Lost funding for Ph... More >>ase II portion of study) Less << - United States, Ohio ... More >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 Less <<
NCT00597116 - Terminated(Recruitment stopped... More >> according to early stopping rule (by protocol)) Less << - -
NCT00508001 Carcinoma, Hepatocellular Phase 2 Completed - Taiwan ... More >> Research Site Tainan, Taiwan Research Site Taipei, Taiwan Research Site Taoyuan, Taiwan Less <<
NCT00753714 - Completed - -
NCT00441142 Glioblastoma Multiforme ... More >> Gliosarcoma Less << Phase 1 Phase 2 Active, not recruiting January 2018 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber / Brigham and Women's Cancer Center Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232-1305 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908-4324 Less <<
NCT00753675 Biliary Tract Cancer ... More >> Gallbladder Cancer Cancer Of The Extrahepatic Bile Duct Ampullary Carcinoma Less << Phase 2 Completed - Italy ... More >> Research Site Brescia, BS, Italy Research Site Firenze, FI, Italy Research Site Genova, GE, Italy Research Site Milano, Mi, Italy Research Site Palermo, PA, Italy Research Site Aviano, PN, Italy Research Site Parma, PR, Italy Research Site Reggio Emilia, RE, Italy Research Site Ancona, Italy Research Site Livorno, Italy Research Site Napoli, Italy Research Site Pisa, Italy Research Site Ravenna, Italy Research Site Rho, Italy Research Site Torino, Italy Less <<
NCT00441142 - Active, not recruiting - -
NCT00807170 Non-small Cell Lung Cancer (NS... More >>CLC) Less << Phase 1 Terminated(Very slow recruitme... More >>nt) Less << - Netherlands ... More >> Research site Amsterdam, Netherlands Research site Groningen, Netherlands Research site Maastricht, Netherlands Less <<
NCT00777179 NSCLC Phase 2 Completed - Korea, Republic of ... More >> Research Site CheongJu, Republic of Korea, Korea, Republic of Research Site Gyeonggi-do, Republic of Korea, Korea, Republic of Research Site Gyeongsangnam-Do, Republic of Korea, Korea, Republic of Research Site Incheon, Republic of Korea, Korea, Republic of Research Site Seoul, Republic of Korea, Korea, Republic of Less <<
NCT00098345 - Completed - -
NCT00500292 - Completed - -
NCT00777179 - Completed - -
NCT01757470 - Completed - Canada, Quebec ... More >> Research Site Montreal, Quebec, Canada Less <<
NCT02268734 - Unknown December 2014 Italy ... More >> Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Recruiting Milano, Italy, 20133 Contact: Laura Locati, MD    +39 022390 ext 2765    laura.locati@istitutotumori.mi.it    Principal Investigator: Laura Locati, MD Less <<
NCT00753675 - Completed - -
NCT00720083 Head and Neck Cancer Phase 2 Terminated(Withdrawal of drug ... More >>supply.) Less << - -
NCT00720083 - Terminated(Withdrawal of drug ... More >>supply.) Less << - -
NCT00667147 Solid Tumors Phase 1 Completed - United States, California ... More >> University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Less <<
NCT00500292 Colorectal Ca... More >>ncer Less << Phase 2 Completed - France ... More >> Research Site Lille Cedex, France Research Site Toulouse Cedex 9, France Hungary Research Site Budapest, Hungary Research Site Debrecen, Hungary Research Site Szeged, Hungary Korea, Republic of Research Site Seoul, Korea, Republic of Slovakia Research Site Bratislava, Slovakia Research Site Poprad, Slovakia Research Site Trnava, Slovakia Research Site Zilina, Slovakia Spain Research Site Hospitalet deLlobregat, Spain Research Site Oviedo, Spain Research Site Santander, Spain Taiwan Research Site Taipei, Taiwan Research Site Tao-Yuan, Taiwan Less <<
NCT00872989 Fallopian Tube Cancer ... More >> Ovarian Cancer Primary Peritoneal Cavity Cancer Less << Phase 2 Completed - -
NCT00872989 - Completed - -
NCT00822887 Malignant Gliomas Phase 1 Completed - United States, Colorado ... More >> University of Colorado Health Science Center Aurora, Colorado, United States, 80045 Less <<
NCT00753714 Non Small Cell Lung Cancer Phase 2 Completed - Italy ... More >> Research Site Meldola, (fc), Italy Research Site Avellino, AV, Italy Research Site Bari, BA, Italy Research Site Treviglio, BG, Italy Research Site Bologna, BO, Italy Research Site Genova, GE, Italy Research Site Taormina, ME, Italy Research Site Milano, MI, Italy Research Site Perugia, PG, Italy Research Site Ravenna, RA, Italy Research Site Trento, TN, Italy Research Site Orbassano, TO, Italy Research Site Udine, UD, Italy Research Site Padova, Italy Research Site Roma, Italy Less <<
NCT00995007 - Completed - -
NCT00687297 Lung Cancer N... More >>on Small Cell Lung Cancer Less << Phase 2 Completed - -
NCT00683787 Gastric Cancer Phase 2 Terminated(low accrual) - United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 Less <<
NCT00687297 - Completed - -
NCT00995007 Glioblastoma Multiforme ... More >> Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Oligoastrocytoma Less << Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00880334 Transitional Cell Carcinoma ... More >> Bladder Cancer Less << Phase 2 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT00880334 - Completed - -
NCT00532909 Anal, Colon, and Rectal Cancer... More >>s Colorectal Neoplasms Colon/Rectal Cancer Less << Phase 1 Completed - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT01372813 Advanced Clear Cell Renal Carc... More >>inoma Less << Phase 2 Terminated(Terminated for insu... More >>fficient accrual.) Less << - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00537095 - Active, not recruiting - -
NCT00757692 Prostate Cancer Phase 2 Completed - Canada, British Columbia ... More >> BC Cancer Agency - Centre for Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Less <<
NCT00683787 - Terminated(low accrual) - -
NCT00862836 Ovarian Cancer PHASE1|PHASE2 TERMINATED 2025-09-10 Research Site, Ulm, Baden-Würt... More >>temberg, Germany|Research Site, Wiesbaden, Hessen, Germany|Research Site, Essen, Nordrhein-Westfalen, Germany|Research Site, Kiel, Schleswig-Holstein, Germany|Research Site, Berlin, Germany Less <<
NCT00537095 Thyroid Neoplasms Phase 2 Active, not recruiting December 31, 2019 Belgium ... More >> Research Site Brussels, Belgium Denmark Research Site Odense, Denmark France Research Site Angers Cedex 9, France Research Site Angers Cedex, France Research Site Bordeaux Cedex, France Research Site Caen Cedex 5, France Research Site Caen Cedex, France Research Site Lyon Cedex, France Research Site Lyon, France Research Site Marseille Cedex 9, France Research Site Marseille Cedex, France Research Site Paris Cedex 10, France Research Site Paris Cedex 13, France Research Site Paris, France Research Site Villejuif Cedex, France Research Site Villejuif, France Norway Research Site Oslo, Norway Spain Research Site L'Hospitalet de Llobregat, Spain Research Site Madrid, Spain Sweden Research Site Lund, Sweden Research Site Stockholm, Sweden Switzerland Research Site Bern, Switzerland Less <<
NCT01945762 - Recruiting September 2019 Belgium ... More >> Research Site Active, not recruiting Brussels, Belgium France Research Site Active, not recruiting Bordeaux, France Research Site Terminated Lyon, France Research Site Recruiting Paris, France Research Site Recruiting Villejuif, France Germany Research Site Recruiting Augsburg, Germany Research Site Active, not recruiting Essen, Germany Research Site Active, not recruiting Heidelberg, Germany Research Site Active, not recruiting Munchen, Germany Italy Research Site Recruiting Catania, Italy Research Site Recruiting MIlano, Italy Research Site Active, not recruiting Milano, Italy Research Site Active, not recruiting Naples, Italy Research Site Recruiting Padova, Italy Research Site Recruiting Pisa, Italy Research Site Recruiting Siena, Italy Luxembourg Research Site Active, not recruiting Luxembourg, Luxembourg Netherlands Research Site Active, not recruiting Groningen, Netherlands Research Site Recruiting Leiden, Netherlands Spain Research Site Recruiting Barcelona, Spain Research Site Active, not recruiting Madrid, Spain Research Site Recruiting Madrid, Spain Research Site Active, not recruiting Oviedo, Spain Research Site Terminated Sevilla, Spain United Kingdom Research Site Terminated Glasgow, United Kingdom Research Site Recruiting London, United Kingdom Research Site Terminated London, United Kingdom Research Site Active, not recruiting Manchester, United Kingdom Research Site Active, not recruiting Sheffield, United Kingdom Research Site Recruiting Sutton, United Kingdom Less <<
NCT01372813 - Terminated(Terminated for insu... More >>fficient accrual.) Less << - -
NCT00862836 Ovarian Cancer PHASE1|PHASE2 TERMINATED 2025-09-10 Research Site, Ulm, Baden-Würt... More >>temberg, Germany|Research Site, Wiesbaden, Hessen, Germany|Research Site, Essen, Nordrhein-Westfalen, Germany|Research Site, Kiel, Schleswig-Holstein, Germany|Research Site, Berlin, Germany Less <<
NCT00445549 Ovarian Neoplasms|Fallopian Tu... More >>be Neoplasms|Peritoneal Neoplasms Less << PHASE2 TERMINATED 2025-10-09 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00445549 Ovarian Neoplasms|Fallopian Tu... More >>be Neoplasms|Peritoneal Neoplasms Less << PHASE2 TERMINATED 2025-10-09 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT01191892 Bladder Cancer ... More >> Transitional Cell Cancer of the Renal Pelvis and Ureter Ureter Cancer Urethral Cancer Less << Phase 2 Unknown December 2014 United Kingdom ... More >> Beatson West of Scotland Cancer Centre Recruiting Glasgow, Scotland, United Kingdom, G12 0YN Contact: Contact Person    44-141-301-7095    Rob.Jones@ggc.scot.nhs.uk    Wales Cancer Trials Unit Recruiting Cardiff, Wales, United Kingdom, CF11 9LJ Contact: Contact Person    44-29-2019-6800       Ayr Hospital Recruiting Ayr, United Kingdom, KA66DX Contact: Margaret McKernan    01563 825749    margaret.mckernan@aaaht.scot.nhs.uk    Principal Investigator: Jawaher Ansari          Royal Bournemouth General Hospital Recruiting Bournemouth, United Kingdom, BH7 7DW Contact: Susannah Brock       susannah.brock@poole.nhs.uk    Principal Investigator: Susannah Brock          Queens Hospital Recruiting Burton upon Trent, United Kingdom, DE13 0RB Contact: Pugazhenthi Pattu    01332 340131    pugazhenthi.pattu@nhs.net    Principal Investigator: Pugazhenthi Pattu          Velindre Hospital Recruiting City and County of Cardiff, United Kingdom, CF142TL Contact: Dr Lester, Jason    44-2920 196159    jason.lester2@wales.nhs.uk    Principal Investigator: Jason Lester          Western General Hospital Recruiting Edinburgh, United Kingdom, EH4 2XU Contact: Duncan McLaren       duncan.mclaren@luht.scot.nhs.uk    Principal Investigator: Duncan McLaren          Calderdale Royal Infirmary Recruiting Halifax, United Kingdom, HX30PW Contact: Lisa Gledhill    01484 342925    lisa.gledhill@cht.nhs.uk    Principal Investigator: Ursula Hofmann          Huddersfield Royal Infirmary Recruiting Huddersfield, United Kingdom, HD3 3EA Contact: Uschi Hofmann    0484 847299    uschi.hofmann@cht.nhs.uk    Principal Investigator: Uschi Hofmann          The Royal Lancaster Infirmary Recruiting Lancaster, United Kingdom, LA1 4RP Contact: Alison Birtle    01524 583219    alison.birtle@lhtr.nhs.uk    Principal Investigator: Alison Birtle          St. James's University Hospital Recruiting Leeds, United Kingdom, LS9 7TF Contact: Satinder Jagdev    0113 2067645    satinder.jagdev@leedsth.nhs.uk    Principal Investigator: Satinder Jagdev          The Royal Free Hospital Not yet recruiting London, United Kingdom, NW3 2QG Principal Investigator: Maria Vilarino-Varela          St Marys Hospital Not yet recruiting London, United Kingdom, W21NY Contact: Gillian Hornzee       Gillian.Hornzee@imperial.nhs.uk    Principal Investigator: Simon Stewart          Charing Cross Hospital Not yet recruiting London, United Kingdom, W68RF Contact: Simon Stewart       simon.stewart@imperial.nhs.uk    Principal Investigator: Simon Stewart          Christie Hospital Recruiting Manchester, United Kingdom, M20 4BX Contact: Tony Eliott    01619187214    tony.eliott@christie.nhs.uk    Principal Investigator: Tony Eliott          Mount Vernon Hospital Recruiting Northwood Middlesex, United Kingdom, HA6 2RN Contact: Peter Hoskin    01923 844533    peter.hoskin@nhs.net    Principal Investigator: Peter Hoskin          Churchill Hospital Recruiting Oxford, United Kingdom, OX37LJ Contact: Georgina Rogers       patpandrewprotheroe@oncology.ox.ac.uk    Principal Investigator: Andrew Protheroe          Weston Park Hospital Recruiting Sheffield, United Kingdom, S102SJ Contact: Linda Evans    0114 226500    linda.evans@sth.nhs.uk    Principal Investigator: Linda Evans          Southampton General Hospital Recruiting Southampton, United Kingdom, S016 6YD Contact: Simon Crabb       s.j.crabb@southampton.ac.uk    Principal Investigator: Simon Crabb          Royal Surrey County Hospital Recruiting Surrey, United Kingdom, GU27XX Contact: Katie Wood    01483 571122    katiewood@nhs.net    Principal Investigator: Katie Wood          The Royal Marsden Hospital Recruiting Surrey, United Kingdom, KT2 7QB Contact: Robert Huddart    020 8661 3457    robert.huddart@icr.ac.uk    Principal Investigator: Robert Huddart Less <<
NCT02015065 GIST PHASE2 COMPLETED 2019-12-10 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT01601808 Pancreatic Cancer Phase 2 Unknown October 2013 United Kingdom ... More >> Belfast City Hospital Not yet recruiting Belfast, United Kingdom, BT9 7AB Principal Investigator: Dr Martin Eatock          The Royal Bournemouth Hospital Recruiting Bournemouth, United Kingdom, BH7 7DW Principal Investigator: Dr Tamas Hickish          Bristol Haematology and Oncology Centre Not yet recruiting Bristol, United Kingdom, BS2 8ED Principal Investigator: Dr Stephen Falk          Royal Surrey County Hospital Recruiting Guildford, United Kingdom, GU2 7XX Principal Investigator: Dr Gary Middleton          Clatterbridge Centre for Oncology Recruiting Liverpool, United Kingdom, CH63 4JY Principal Investigator: Professor Daniel Palmer          Royal Liverpool University Hospital Recruiting Liverpool, United Kingdom, L69 3GA Principal Investigator: Professor Daniel Palmer          St Bartholomew's Hospital Not yet recruiting London, United Kingdom, EC1A 7BE Principal Investigator: Dr David Propper          Guys & St Thomas Hospital Recruiting London, United Kingdom, SE1 9RT Principal Investigator: Dr Paul Ross          Royal Marsden Hospital Not yet recruiting London, United Kingdom, SW3 6JJ Principal Investigator: Professor David Cunningham          The Christie Hospital Recruiting Manchester, United Kingdom, M20 4BX Principal Investigator: Dr Richard Hubner          James Cook University Hospital Recruiting Middlesbrough, United Kingdom, TS4 3BW Principal Investigator: Dr Nick Wadd          Freeman Hospital Not yet recruiting Newcastle, United Kingdom, NE7 7DN Principal Investigator: Dr Fareeda Coxon          Nottingham City Hospital Recruiting Nottingham, United Kingdom, NG5 1PB Principal Investigator: Dr Srinivasan Madhusudan          Weston Park Hospital Recruiting Sheffield, United Kingdom, S10 2SJ Principal Investigator: Dr Jonathan Wadsley Less <<
NCT00996723 Diffuse Intrinsic Pontine Glio... More >>ma Less << Phase 1 Completed - United States, Tennessee ... More >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less <<
NCT00660725 Advanced Incurable Solid Malig... More >>nancy Less << Phase 1 Completed - United States, Pennsylvania ... More >> University of Pittsburgh Cancer Institute / Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT00514046 Medullary Thyroid Carcinoma|Mu... More >>ltiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B Less << PHASE1|PHASE2 COMPLETED 2020-11-01 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT01941849 Phaeochromocytoma ... More >> Paraganglioma Less << Phase 1 Withdrawn(Poor patient accrual... More >>) Less << - United Kingdom ... More >> Guy's and St Thomas' NHS Foundation Trust London, United Kingdom The Christie NHS Foundation Trust London, United Kingdom University College London Hospitals NHS Foundation Trust London, United Kingdom Less <<
NCT01496313 Thyroid Cancer Phase 4 Active, not recruiting December 2019 United States, Texas ... More >> Research Site Houston, Texas, United States Czech Republic Research Site Olomouc, Czech Republic Research Site Praha 5, Czech Republic India Research Site Bangalore Karnataka, India Research Site Vellore, India Israel Research Site Beer Sheva, Israel Research Site Haifa, Israel Research Site Jerusalem, Israel Research Site Petach Tikva, Israel Italy Research Site Catania, Italy Research Site Milano, Italy Research Site Palermo, Italy Research Site Pisa, Italy Research Site Roma, Italy Research Site Siena, Italy Research Site Torino, Italy Netherlands Research Site Groningen, Netherlands Research Site Leiden, Netherlands Poland Research Site Gliwice, Poland Research Site Warszawa, Poland Research Site Zgierz, Poland Russian Federation Research Site Saint Petersburg, Russian Federation United Kingdom Research Site Cardiff, United Kingdom Research Site Greater London, United Kingdom Research Site London, United Kingdom Research Site Tyne & Wear, United Kingdom Less <<
NCT01004419 Carcinoma, Non Small Cell Lung Phase 1 Withdrawn(Support for investig... More >>ational products has been withdrawn.) Less << May 2011 -
NCT00472017 Brain and Central Nervous Syst... More >>em Tumors Less << Phase 1 Completed - United States, Tennessee ... More >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less <<
NCT02495103 Renal Cell Carcinoma ... More >> Hereditary Leiomyomatosis and Renal Cell Cancer Papillary Renal Cell Carcinoma, Sporadic Less << Phase 1 Phase 2 Recruiting May 1, 2022 United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT02530411 Neoplasms Phase 2 Recruiting December 2020 United Kingdom ... More >> Royal Bournemouth Hospital Recruiting Bournemouth, Dorset, United Kingdom, BH7 7DW Contact: Tamas Hickish, MA MD FRCP    01202 704789    tamashickish@rbch.nhs.uk    Royal Devon and Exeter Hospital Recruiting Exeter, England, United Kingdom, EX2 5DW Contact: Anne Hong, MB ChB MRCP    01392 402118    anne.hong@nhs.net    Royal Cornwall Hospital Recruiting Truro, Cornwall, England, United Kingdom, TR1 3LJ Contact: Duncan Wheatley, MBBS, FRCR    01872 258304    duncan.wheatley@rcht.cornwall.nhs.uk    Velindre Cancer Center, Velindre Hospital Recruiting Cardiff, Wales, United Kingdom, CF14 2TL Contact: Robert Jones, MD PhD MCRCP    029 2061 5888    robert.jones14@wales.nhs.uk    Royal United Hospital Bath Recruiting Bath, United Kingdom, BA1 3NG Contact: Mark Beresford, MD MRCP FRCR    01225 824797    mark.beresford@nhs.net Less <<
NCT01586624 Cancer Non Sm... More >>all Cell Lung Cancer Less << Phase 1 Active, not recruiting March 2019 United Kingdom ... More >> Cambridge Cancer Trials Centre (S4), Box 279, Addenbrooke's Hospital Hills Road, Cambridge, United Kingdom, CB2 0QQ The Christie NHS Foundation Trust Withington, Manchester, United Kingdom, M20 4BX Churchill Hospital Headington, Oxford, United Kingdom, OX3 7LJ The Freeman Hospital Newcastle, United Kingdom, NE7 7DN Less <<
NCT00923247 - Terminated(Terminated due to s... More >>low accrual,primary endpoint reached & investigator left NIH.) Less << - -
NCT00923247 Medullary Thyroid Carcinoma Phase 1 Phase 2 Terminated(Terminated due to s... More >>low accrual,primary endpoint reached & investigator left NIH.) Less << - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT02109250 - Completed - Belgium ... More >> Clinique du Sud Luxembourg Arlon, Belgium, 6700 AZ Klina Brasschaat, Belgium, 2930 Institut Jules Bordet Brussels, Belgium, 1000 UZ Brussel Brussels, Belgium, 1090 UCL St-Luc Brussels, Belgium, 1200 UZ Gent Gent, Belgium, 9000 AZ Delta Roeselare, Belgium, 8800 CH de Wallonie Tournai, Belgium, 7500 Less <<
NCT00821080 Glioblastoma Phase 1 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Instiute Boston, Massachusetts, United States, 02115 Less <<
NCT01582191 Advanced Cancers Phase 1 Recruiting May 2026 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT01934335 Invasive Breast Cancer Phase 2 Suspended(Drugs unavailable) July 2019 United States, Iowa ... More >> University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 Less <<
NCT01876784 - Active, not recruiting - -
NCT01876784 Differentiated Thyroid Cancer Phase 3 Active, not recruiting December 31, 2019 -
NCT01298323 Locally Advanced or Metastatic... More >> Medullary Thyroid Cancer Medullary Thyroid Cancer Less << Phase 3 Active, not recruiting December 31, 2019 -
NCT01496313 - Active, not recruiting - -
NCT00613223 Gliosarcoma G... More >>lioblastoma Less << Phase 1 Completed - United States, North Carolina ... More >> Duke University Health System Durham, North Carolina, United States, 27710 Less <<
NCT01298323 - Active, not recruiting - -
NCT01661179 Unresectable Locally Advanced ... More >>or Metastatic, Medullary Thyroid Carcinoma Less << Phase 1 Phase 2 Completed - Japan ... More >> Research Site Fukuoka-shi, Japan Research Site Kobe-shi, Japan Research Site Koto-ku, Japan Research Site Shinjuku-ku, Japan Less <<
NCT01661179 - Completed - -
NCT01539655 Medullary Thyroid Cancer Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT01551615 Healthy Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT00566995 Renal Cancer ... More >>Von Hippel Lindau Less << Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01823068 Non Small Cell Lung Cancer PHASE2 COMPLETED 2018-03-16 Seoul National University Hosp... More >>ital, Seoul, 110744, Korea, Republic of|Samsung Medical Center, Seoul, 135710, Korea, Republic of Less <<
NCT01561781 Healthy Volunteers Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT03291379 Carcinoma, Hepatocellular ... More >> Metastatic Colorectal Cancer Less << Early Phase 1 Recruiting January 2019 United Kingdom ... More >> University College London Hospital Recruiting Bloomsbury, London, United Kingdom, NW1 2BU Contact: Professor Ricky Sharma Less <<
NCT00566995 - Completed - -
NCT01544140 Healthy Volunteers Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT00402896 Lung Cancer|Pleural Effusion PHASE2 TERMINATED 2025-06-14 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT00034918 Breast Neoplasms|Metastases, N... More >>eoplasm Less << PHASE2 COMPLETED 2025-11-03 Research Site, Indianapolis, I... More >>ndiana, United States|Research Site, Barcelona, 08035, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.52mL

2.10mL

1.05mL

21.04mL

4.21mL

2.10mL

References

 

Historical Records

Categories